Trademarkia Logo

Canada

C$
DICERNA
REGISTERED

on 5 Dec 2022

Last Applicant/ Owned by

DICERNA PHARMACEUTICALS INC.

87 Cambridgepark DriveCambridge, MA 02140

US

Serial Number

1929867 filed on 9th Nov 2018

Registration Number

TMA1154694 registered on 5th Dec 2022

Registration expiry Date

5th Dec 2032

Correspondent Address

CPST INTELLECTUAL PROPERTY INC.

130 Queens Quay EastEast Tower, Suite 809Toronto,

ONTARIO

CA

M5A0P6

DICERNA

Trademark usage description

pharmaceutical preparations for the treatment of various diseases, namely, rare metabolic, endocrine, cardiac, oncological, gastrointestinal, nephrolo Read More

Classification Information


Class [005]
Pharmaceutical preparations for the treatment of various diseases, namely, rare metabolic, endocrine, cardiac, oncological, gastrointestinal, nephrological, autoimmune, and neurological diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Oligonucleotide compounds for use in the targeted delivery of RNAi therapy; Pharmaceutical preparations for use in targeted pharmaceutical therapies for the treatment of various diseases, namely, rare metabolic, endocrine, cardiac, oncological, gastrointestinal, nephrological, autoimmune, and neurological diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Chemical compounds in the form of a molecular nanoparticle complex that act as a platform for the delivery of RNA-based drugs to biological cells; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies


Classification kind code

11

Class [042]
Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; research and development of pharmaceutical preparations for the treatment of liver-based disorders; research and development of oligonucleotide compounds for targeted gene silencing; scientific research and development for the treatment of various diseases, namely rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, and cancers and viral infections; scientific investigations in the fields of rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, and cancers and viral infections for medical purposes; providing medical and scientific research information in the field of pharmaceuticals and clinical trials


Classification kind code

11

Mark Details


Serial Number

1929867

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 27
on 1st Feb 2022
Approval Notice Sent
Submitted for opposition 26
on 1st Feb 2022
Approved
Submitted for opposition 23
on 26th Jan 2022
Default Removed
Submitted for opposition 14
on 29th Dec 2021
Default Notice Sent
Submitted for opposition 48
on 20th Oct 2021
Agent Changed
Submitted for opposition 22
on 14th May 2021
Search Recorded
Submitted for opposition 20
on 14th May 2021
Examiner's First Report
Submitted for opposition 31
on 15th Nov 2018
Formalized
Submitted for opposition 1
on 13th Nov 2018
Created
Submitted for opposition 30
on 9th Nov 2018
Filed